RHOA and prostate carcinoma: Interestingly, we found that RhoA inhibition was predominantly effective in LNCaP prostate cancer cells, which aligns with the previously demonstrated importance of RhoA in this type of malignancy and suggests combined co-inhibition of RhoA and SRCs as a potential treatment for prostate cancer100,101.